1. Home
  2. ABEO vs JRVR Comparison

ABEO vs JRVR Comparison

Compare ABEO & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABEO
  • JRVR
  • Stock Information
  • Founded
  • ABEO N/A
  • JRVR 2002
  • Country
  • ABEO United States
  • JRVR Bermuda
  • Employees
  • ABEO N/A
  • JRVR N/A
  • Industry
  • ABEO Biotechnology: Pharmaceutical Preparations
  • JRVR Property-Casualty Insurers
  • Sector
  • ABEO Health Care
  • JRVR Finance
  • Exchange
  • ABEO Nasdaq
  • JRVR Nasdaq
  • Market Cap
  • ABEO 277.6M
  • JRVR 241.0M
  • IPO Year
  • ABEO 1980
  • JRVR 2005
  • Fundamental
  • Price
  • ABEO $6.41
  • JRVR $6.45
  • Analyst Decision
  • ABEO Strong Buy
  • JRVR Buy
  • Analyst Count
  • ABEO 3
  • JRVR 6
  • Target Price
  • ABEO $18.00
  • JRVR $11.17
  • AVG Volume (30 Days)
  • ABEO 290.2K
  • JRVR 251.1K
  • Earning Date
  • ABEO 11-11-2024
  • JRVR 11-05-2024
  • Dividend Yield
  • ABEO N/A
  • JRVR 3.10%
  • EPS Growth
  • ABEO N/A
  • JRVR N/A
  • EPS
  • ABEO N/A
  • JRVR N/A
  • Revenue
  • ABEO N/A
  • JRVR $815,639,000.00
  • Revenue This Year
  • ABEO N/A
  • JRVR N/A
  • Revenue Next Year
  • ABEO $7,097.06
  • JRVR $8.37
  • P/E Ratio
  • ABEO N/A
  • JRVR $3.41
  • Revenue Growth
  • ABEO 147.52
  • JRVR 23.89
  • 52 Week Low
  • ABEO $3.05
  • JRVR $6.12
  • 52 Week High
  • ABEO $9.01
  • JRVR $15.47
  • Technical
  • Relative Strength Index (RSI)
  • ABEO 61.15
  • JRVR 47.99
  • Support Level
  • ABEO $6.39
  • JRVR $6.14
  • Resistance Level
  • ABEO $6.74
  • JRVR $6.64
  • Average True Range (ATR)
  • ABEO 0.31
  • JRVR 0.21
  • MACD
  • ABEO 0.02
  • JRVR 0.04
  • Stochastic Oscillator
  • ABEO 68.57
  • JRVR 63.46

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

About JRVR James River Group Holdings Ltd.

James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure. and the Corporate and other segment consists of the management and treasury activities of holding companies, equity compensation for the group.

Share on Social Networks: